Story perspectives

CVS Stock Soars 76%, Analysts Call It Undervalued

10/16/2025

32 3

Summary

Story summary

CVS Health's stock increased by 76% year-to-date as of mid-October 2025, outperforming the market.
Analysts consider CVS undervalued, noting a forward P/E ratio of 10.7 versus the healthcare sector's average of 17.3.
Strong Q2 earnings, particularly from the Health Care Benefits segment, have contributed to positive sentiment.
CVS is shifting its strategy from membership growth to improving profit margins within its integrated healthcare model.
Eli Lilly and Cardinal Health also reported strong performances, with Eli Lilly raising its full-year outlook and Cardinal Health expanding its distribution network.

1 of 1

Story summary

CVS Health's stock increased by 76% year-to-date as of mid-October 2025, outperforming the market.
Analysts consider CVS undervalued, noting a forward P/E ratio of 10.7 versus the healthcare sector's average of 17.3.
Strong Q2 earnings, particularly from the Health Care Benefits segment, have contributed to positive sentiment.
CVS is shifting its strategy from membership growth to improving profit margins within its integrated healthcare model.
Eli Lilly and Cardinal Health also reported strong performances, with Eli Lilly raising its full-year outlook and Cardinal Health expanding its distribution network.